Methodology: 3.5/5
Usefulness: 3/5

Bourke EM, et al. Ann Emerg Med. 2025 Jul;86(1):1-11. doi: 10.1016/j.annemergmed.2025.01.007. 

Question and Methods: In this randomized, open-label, multicentre trial, the authors investigated whether oral olanzapine was more effective than oral diazepam for achieving sedation in acutely agitated children and adolescents, aged 9-17 years old. The primary outcome was successful sedation (Sedation Assessment Tool score of 0) at one-hour post-randomization without the need for additional medications.
Findings: Successful sedation without the requirement for additional sedatives occurred in 61% in the olanzapine group and 57% in the diazepam group. No serious adverse events were reported in either group.
Limitations: Due to the open-label design, this trial was not blinded and is at risk of bias. Additional limitations include lack of details regarding alternative strategies for de-escalation or agitation management, as well as outcomes relating to escalating violence management (e.g., physical restraints, additional/more invasive chemical restraint).

Interpretation: Olanzapine and diazepam are similarly effective and safe for pediatric ED agitation, but neither is consistently effective, as 40% of participants in each group were not considered adequately sedated.

Dr. Isabella Menchetti

JC Supervisor: Dr. Krishan Yadav

 


 

Authors

  • Dr. Isabella Menchetti is an FRCPC Emergency Medicine resident at the University of Ottawa.

    View all posts
  • Dr. Hans Rosenberg

    Dr. Rosenberg is an emergency physician at the Ottawa Hospital, associate professor at the University of Ottawa, and Director of the Digital Scholarship and Knowledge Dissemination Program.

    View all posts
  • Dr. Krishan Yadav is an FRCPC Emergency Medicine Physician, and Epidemiologist with a special interest in non-purulent skin and soft tissue infectious disease.

    View all posts

Subscribe to get updated on our latest posts!

Join our mailing list to receive the latest posts from our team (once a week only!).

You have Successfully Subscribed!